1. Scrip
  2. >>Focus On Asia
  3. >>China

Chinese Firms Expand Solo Global Phase III Activity Including US Sites

Indicative Of Independent Growth

 
• By Dexter Jie Yan

Throughout 2024, Chinese firms as sole sponsors initiated a total of seven global Phase III trials that including US sites. BeiGene, Genfleet and InnoCare are expected to add four similar studies this year.

from 2024 to 2025
2024's seven global Phase III trials opened solely by Chinese firms was the second least since 2020. (Shutterstock)

Throughout 2024 and against persistent financial headwinds, novice and returning sole Chinese company sponsors of clinical trials initiated a total of seven new global Phase III programs that included sites in the US.

Despite the past year being outshone by 2023, 2021 and 2020, when the number of similar trials with Chinese-developed drug candidates was 10, a record 11 and eight respectively, 2024 still saw one more such

Key Takeaways
  • In 2024, RemeGen, Ascentage and Henlius were among the Chinese drug makers initiating a total of seven global Phase III trials that included US sites.
  • Looking ahead, BeiGene (BeOne Medicines), Genfleet and InnoCare are expected to start four other similar trials this year

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

Hengrui Set For Biggest Biopharma IPO So Far This Year

 
• By Dexter Jie Yan

Jiangsu Hengrui Pharmaceuticals is gearing up for what will be 2025's biggest biopharma IPO so far, hoping to raise up to $1.27bn on the Hong Kong Stock Exchange. China's top drug maker by pipeline size plans to use part of the proceeds to reboot its overseas clinical trials ambitions.

China Biopharma Podcast

 
• By Dexter Jie Yan and Xu Hu

Join our China-based editors Dexter Yan and Xu Hu in this Chinese-language podcast looking at some of their recent interviews and other key coverage.

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor For IPF

 
• By Dexter Jie Yan

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.

Chinese Vaccine Makers Turn To Emerging Markets

 
• By Dexter Jie Yan

Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales.

More from Scrip Perspectives

Scrip Asks... What Does 2025 Hold For Biopharma? Part 5: Clinical Trials Trends

 
• By Eleanor Malone

A revolution is underway. Technology offers the possibility to transform multiple aspects of the traditional gold standard of drug development: the randomized controlled trial. Sharing their insights with Scrip, 30 thought leaders consider how the clinical trial landscape will evolve in 2025.

Tech, India Trends To Track: AI Agents, SaaS Disruption, Influencers, Insurance

 
• By Anju Ghangurde

Industry pundits talk about conversational AI for sales reps, the arrival of AI agents, a potential overhaul in the SaaS market for pharma enterprises and the tricky arena of influencer engagement in this instalment on key trends playing out on the tech front and in India. Expanding healthcare coverage is also improving the outlook for pharma in the country, they said.

Scrip Asks... What Does 2025 Hold For Biopharma? Part 4: Artificial Intelligence and Data Science

 
• By Eleanor Malone

More than 50 executives across industry share their expectations for the impact of AI on the biopharma industry over the coming year. While target identification and drug discovery featured highly, the opportunities to engage with patients and healthcare providers more effectively and the need for suitable regulatory frameworks were also flagged up.